|Scientific Subdivisions | The Journal of Molecular Diagnostics
Contact AMP | Sign In | Join / Renew | Go To CHAMP
AMP 2014 Annual Meeting
AMP CELEBRATES 20 YEARS!
November 13 -15, 2014
For More Information
Corporate Workshop Day & Gala, November 12, 2014
Gaylord National Resort & Convention Center
National Harbor, MD (just outside of Washington, DC)
March 2014: AMP outlines significant concerns regarding sweeping changes to the Clinical Laboratory Fee Schedule (CLFS) in SGR patch legislation, submits letter to House Majority Leader.
Planning to exhibit at the AMP 2014 Annual Meeting? The early booking (discounted rates!) deadline has been extended to May 1, 2014. More information....
December 2013: the January 2014 JMD article proposes new, service-oriented terminology - Laboratory Developed Procedures (LDPs). "The new term accurately describes the integral expertise of the clinical laboratory professional," said Andrea Ferreira-Gonzalez, Chair, AMP LDT Working Group.
October 2013: Comments detail concerns about the Palmetto Molecular Diagnostics (MolDX) Services Program and Medicare coverage as well as their impact on Gap Fill Pricing for Molecular Pathology Procedures.
September 2013: In the past four weeks, AMP has submitted comments to the CMS and Palmetto on issues related to reimbursement and patient care. AMP will continue to advocate on behalf of its members and the field of molecular diagnostics.
View the most recent edition of AMPlifications including updates on AMP's education, advocacy, and patient care-related initiatives.
June 2013: AMP has joined the Federation of American Societies for Experimental Biology (FASEB). "Being a member of FASEB will enable AMP's voice to be even stronger," said Jennifer L. Hunt, MD, MEd, AMP President.
AMP is very pleased with the Supreme Court’s decision in the case. The Court’s decision that human genes are not patentable is a great step forward for the field of molecular pathology, for genomic science, and most important for our patients. We look forward to exciting future advancements in diagnostic testing and therapeutics that will accrue to the benefit of our patients and our field.
Link to decision from Supreme Court of the United States: http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf
May 2013: A coalition representing over 120,000 medical and laboratory professionals and institutions that perform the vast majority of clinical molecular pathology testing in the United States released a joint statement regarding new Medicare prices for those tests.
The guideline was developed to establish standards for testing for EGFR and ALK, helping to guide targeted therapies. Pathologists are encouraged to implement the new guideline at their institutions and into their practices to help improve the effectiveness of lung cancer treatment. More information...
View the webcast (wmv file)